News | September 23, 2008

MammoSite RT Recurrence Rates Comparable to Standard RT

September 24, 2008 - Hologic Inc. released a four-year analysis of the Hologic MammoSite radiation therapy system study, which found that breast cancer recurrence rates following the delivery of accelerated partial breast irradiation with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy.

The study was presented by Peter Beitsch, M.D., of Medical City Dallas Hospital at ASTRO 2008. Beitsch and his colleagues analyzed data from patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial.

The researchers reported that their analysis of the overall registry population with a median follow-up of 36 months showed a three-year actuarial rate of Ipsilateral Breast Tumor Recurrence (IBTR) of 2.15 percent. Other follow-up results were also positive (0.26 percent three-year actuarial rate for axillary recurrences and 0.74 percent three-year actuarial rate for new primary cancers).

In a subset of patients (the first 400 treated), 44-month follow-up data was captured and a 93.9 percent survival rate was reported (88.9 percent disease-free and 100 percent cancer-specific). The researchers concluded that treatment with the MammoSite system resulted in low IBTR, low axillary recurrence, and acceptable cancer specific survival.

The MammoSite device is a balloon catheter that is inserted into the cavity created by a lumpectomy (the surgical removal of a breast tumor). The MammoSite radiation therapy system delivers radiation from inside the lumpectomy cavity over a course of five days. The device targets radiation to the area where tumors are most likely to recur, while reducing exposure to healthy tissue.

For more information: www.hologic.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init